Figure 12.2 Reference diameter and late loss in the stent arm of 6 randomized trials

It is worth noting that restenosis was relatively common after treatment of ostial lesions. Placement of drug-eluting stents at ostial lesions may constitute a challenging technical problem in accomplishing complete lesion scaffolding. Post-sirolimus-eluting stent restenosis is commonly associated with a discontinuity in stent coverage, which may be of particular concern for ostial (and bifurcation) lesions (see Chapter 18). Drug-eluting stents especially designed for these lesions may be needed to improve the outcomes in this setting.